What is 'Abbreviated New Drug Submission (ANDS)'

An Abbreviated New Drug Submission (ANDS) is a written request to Health Canada to obtain marketing approval for a generic drug. An Abbreviated New Drug Submission must be approved by Health Canada, the country’s federal department in charge of national health care, under Canada’s Food and Drug regulations, before the generic drug can be marketed in the country. An ANDS provides the necessary information for the government agency to evaluate how safe and effective a generic drug is compared with its brand-name equivalent. The generic must be equally safe and effective to gain approval.

BREAKING DOWN 'Abbreviated New Drug Submission (ANDS)'

An Abbreviated New Drug Submission is used to obtain approval for generic drugs. This is in contrast to a New Drug Submission (NDS), which is used to obtain approval for a new brand-name drug. An ANDS lists the related drug’s brand name, chemical name, manufacturer name, dosage form(s) and strength(s). It states whether the drug has already been approved for marketing in the United States, the European Union, Switzerland, Singapore and/or Australia. It also addresses questions about drug impurities and drug stability.

Generic drugs are biologically equivalent to the brand-name drugs on which they are based. They are comparable in dosage form, strength, route of administration, quality, performance characteristics and intended use. They are designated "abbreviated" because pre-clinical and clinical data is not required to establish their safety and efficacy.

An ANDS supplies information regarding data on studies comparing the proposed drug to the approved brand-name drug, called the “reference drug,” and asks for data from studies conducted on the generic drug. For example, for drugs with delivery devices, the ANDS states whether there have been studies comparing the physical and operating characteristics of the brand-name device with those of the proposed generic device. For tablets, it states whether the proposed generic drug has been scored like the brand name so the generic tablet can be divided similarly to the brand name tablet. The ANDS also supplies information about studies comparing the bioavailability of the brand name drug with that of the proposed generic drug, and about the results of bacterial endotoxin tests for sterile drugs. The applicant must pay a fee in conjunction with its ANDS.

ANDS and Biotechnology Investments

One way for investors to evaluate biotechnology companies is to examine their pipeline of ANDS. A company with a high number of pending ANDS relative to its competitors may end up with more generic drugs to sell and therefore be more profitable. 

RELATED TERMS
  1. Orange Book

    The Orange Book is a list of drugs that the U.S. Food and Drug ...
  2. New Drug Application (NDA)

    The New Drug Application (NDA) is the formal final step taken ...
  3. Phase 4

    Phase 4 refers to the final stage of new drug testing, which ...
  4. Phase 2

    Phase 2 is the second phase of clinical trials for an experimental ...
  5. Food And Drug Administration (FDA)

    The Food and Drug Administration is a government agency that ...
  6. Healthcare Sector

    The healthcare sector consists of companies that provide medical ...
Related Articles
  1. Investing

    Market Vectors Launches First Generic Drugs ETF (GNRX)

    Generic drugs have been a growing market in recent years. Now there is an ETF targeted at this market.
  2. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  3. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  4. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  5. Insights

    Why Drug Prices Keep Rising & How to Fight Back

    Despite pushback from politicians and disgruntled consumers, the cost of drugs keeps going up. Is there any relief on the horizon?
  6. Investing

    Generics Won't Be Delayed by Citizen Petition Rule

    The Citizen Petition rule, often used as a tool to delay generic drug launches, was amended by the FDA to stop its misuse.
  7. Insurance

    The Cancer (and Other Drug) Shortage

    Your doctor may not tell you, but even in the U.S., life-saving drugs can be in short supply. Here's what to know and do.
  8. Insights

    How Teva Is Fighting (and Losing) the Big Pharma Battle

    Teva is still the largest generics drugmaker in the world but struggles to catch up with big pharmaceutical companies boosted by brand name drugs.
  9. Investing

    Samsung Wants to Become a Drug Company

    Samsung is expanding its drug efforts, inking a deal to create drugs for hard-to-treat diseases.
  10. Insights

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
RELATED FAQS
  1. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  2. Can your insurance company drug test you?

    Learn why insurance companies conduct drug tests and how a lifestyle free of drugs can save you big money on health and life ... Read Answer >>
  3. Who are Pfizer's (PFE) main competitors?

    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ... Read Answer >>
  4. What Does Orphan Drug Status Mean?

    One type of incentive is the orphan drug status, which gives companies researching cures for rare diseases and the rights ... Read Answer >>
  5. Who are Amgen Inc.'s (AMGN) main competitors?

    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with. Read Answer >>
  6. Biotech vs Pharmaceutical company

    Though biotech and pharmaceutical companies share similar business features, there also have differences. Here, we'll distinguish ... Read Answer >>
Trading Center